Arax Advisory Partners’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35K Sell
2,282
-343
-13% -$6.57K ﹤0.01% 3614
2026
Q2
$47.8K Buy
2,625
+2,275
+650% +$33.8K ﹤0.01% 3296
2026
Q1
$4.97K Buy
350
+178
+103% +$2.29K ﹤0.01% 2784
2025
Q4
$1.78K Sell
172
-1,268
-88% -$11.4K ﹤0.01% 3304
2025
Q3
$8.54K Buy
+1,440
New +$10.5K ﹤0.01% 2667
2024
Q4
– Sell
-7
Closed -$118 – 2485
2024
Q3
$118 Hold
7
– – ﹤0.01% 2549
2024
Q2
$123 Buy
+7
New +$149 ﹤0.01% 2477

Other funds holding CGEM

Arax Advisory Partners's CGEM Position: Q3 2026 in Review

Arax Advisory Partners reduced its Cullinan Therapeutics (CGEM) stake by 13% in Q3 2026, selling an estimated $6.57K and leaving 2,282 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Arax Advisory Partners first reported a position in CGEM in Q2 2024 and has held it in 7 quarters since. The position peaked at $47.8K in Q2 2026. 153 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Arax Advisory Partners held 2,282 shares of Cullinan Therapeutics worth $35K as of Q3 2026.
  • Arax Advisory Partners sold 343 Cullinan Therapeutics shares in Q3 2026, an estimated $6.57K.
  • Cullinan Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3614 holding.
  • Arax Advisory Partners first reported a position in Cullinan Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Cullinan Therapeutics position peaked at $47.8K in Q2 2026.
  • 153 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.